pitavastatin vs sofosbuvir/velpatasvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of pitavastatin and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
pitavastatin ↑ pitavastatin Coadministration with VOSEVI may increase the concentration of pitavastatin and is not recommended, due to an increased risk of myopathy, including rhabdomyolysis.
Livalo
Epclusa
Pitavastatin (Livalo) is a drug that helps lower bad cholesterol (LDL-C) in your blood. It is used along with a healthy diet.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
Pitavastatin is used to lower LDL-C (bad cholesterol) in adults. It is for adults who have high cholesterol or who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). This medicine works best when you also follow a low-cholesterol diet.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Pitavastatin belongs to a class of drugs called statins. It works by blocking a substance your body needs to make cholesterol. This helps to lower the amount of cholesterol in your blood.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Muscle pain
- • Constipation
- • Back pain
- • Diarrhea
- • Pain in your arms or legs
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- Myalgia 408
- Diarrhoea 335
- Dizziness 285
- Dyspnoea 281
- Decreased Appetite 280
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
Pitavastatin can cause muscle problems, including myopathy and rhabdomyolysis. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. Pitavastatin can also cause liver problems. Your doctor may do blood tests to check your liver before and during treatment.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Do not take pitavastatin if you are pregnant. It can harm your unborn baby. Breastfeeding is also not recommended while taking this medicine.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare pitavastatin with
How to Read This pitavastatin vs sofosbuvir/velpatasvir Comparison
pitavastatin is classified in the HMG-CoA Reductase Inhibitor (Statin) drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, pitavastatin has 1,589 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to the hepatitis c medicine increases the amount of pitavastatin that stays in your blood. this happens because the medicine interferes with how your body normally processes and removes the cholesterol drug.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for pitavastatin or sofosbuvir/velpatasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.